In research published online on March 11, 2013 in the Journal of Clinical Oncology, researchers report on the results of a phase III, double-blind, placebo-controlled multicenter study that evaluated whether using abagovomab as maintenance therapy prolongs recurrence-free survival and overall survival in patients with ovarian cancer in patients in their first remission.
This clinical trial was organized by Dr. Jonathan Berek and the Cooperative Ovarian Cancer Group for Immunotherapy, a consortium of ovarian cancer researchers created with funding from OCRF.
Results of the trial showed that abagovomab, administered as repeated monthly injections, is safe and induces a measurable immune response. However, administration as maintenance therapy for patients with ovarian cancer in first remission was not found to prolong recurrence-free survival or overall survival.
Click here to read the abstract.